Our findings suggest that the novel combination of alpelisib and onvansertib presents a promising therapeutic strategy and warrants clinical exploration of this regimen for HR+ breast cancer patients progressing on CDK4/6i and ET. The gene discussed is CDK4; the disease is breast cancer.